Acute changes of coagulation and fibrinolysis parameters after experimental thromboembolic stroke and thrombolytic therapy

Neuroscience Letters

Volumn 441, Issue 1, 2008, Pages 39-43

  Stehling, Florian ^a   Weber, Ralph ^a   Özcelik, Arzu ^a   Bröcker, Martina ^a   Volbracht, Lothar ^a   Diener, Hans Christoph ^a   Busch, Elmar ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Coagulation; Fibrinolysis; Rat; Recombinant tissue plasminogen activator; Thromboembolic stroke

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALTEPLASE; ANTIGEN; ANTIPLASMIN; ANTITHROMBIN III; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; THROMBIN TIME; THROMBOEMBOLISM;

ANIMALS; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; FIBRINOLYSIS; MALE; PLASMINOGEN; RATS; RATS, WISTAR; STROKE; THROMBOEMBOLISM; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 46149112968     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.05.102     Document Type: Article

References (34)

1. Aoshima K., Asakura H., Yamazaki M., Saito M., Kumabashiri I., Morishita E., Ontachi Y., Mizutani T., Ichino T., and Matsuda T. Treatment of disseminated intravascular coagulation (DIC) with all-trans retinoic acid in an endotoxin-induced rat model. Semin. Thromb. Hemost. 24 (1998) 227-231
2. Asahi M., Asahi K., Wang X., and Lo E.H. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 20 (2000) 452-457
3. Bangert K., and Thorsen S. Assay of functional plasminogen in rat plasma applicable to experimental studies of thrombolysis. Thromb. Haemost. 84 (2000) 299-306
4. Bloom J.C., Sellers T.S., Gries G.C., Wheeldon E.B., O'Brien S.R., and Lewis H.B. The effect of human recombinant tissue-type plasminogen activator on clinical and laboratory parameters of hemostasis and systemic plasminogen activation in the dog and the rat. Thromb. Haemost. 60 (1988) 271-279
5. Busch E., Kruger K., and Hossmann K.A. Improved model of thromboembolic stroke and rt-PA induced reperfusion in the rat. Brain Res. 778 (1997) 16-24
6. Chabielska E., Kolpakov V., D'Adamo M.C., De Curtis A., Buczko W., Iacoviello L., and Donati M.B. Morphological and hemostatic changes in rats with abdominal arterial prosthesis. Thromb. Res. 82 (1996) 69-77
7. Chandler W.L., Alessi M.C., Aillaud M.F., Henderson P., Vague P., and Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 96 (1997) 761-768
8. Del Zoppo G.J. Focal cerebral ischemia and hemostasis: a PAI-1 conundrum. J. Thromb. Haemost. 3 (2005) 1376-1378
9. Dudani A.K. Plasminogen and tissue plasminogen activator interact with antithrombin III. Thromb. Res. 99 (2000) 635-641
10. Feinberg W.M., Erickson L.P., Bruck D., and Kittelson J. Hemostatic markers in acute ischemic stroke. Association with stroke type, severity, and outcome. Stroke 27 (1996) 1296-1300
11. Genser N., Lechleitner P., Maier J., Dienstl F., Artner-Dworzak E., Puschendorf B., and Mair J. Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used. Clin. Chem. 44 (1998) 209-214
12. Gonda Y., Hirata S., Saitoh K., Aoki Y., Mohri M., Gomi K., Sugihara T., Kiyota T., Yamamoto S., Ishida T., and Maruyama I. Antithrombotic effect of recombinant human soluble thrombomodulin on endotoxin-induced disseminated intravascular coagulation in rats. Thromb. Res. 71 (1993) 325-335
13. Harpel P.C. Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. J. Clin. Invest. 68 (1981) 46-55
14. Ho C.H., and Wang S.P. Serial thrombolysis-related changes after thrombolytic therapy with TPA in patients with acute myocardial infarction. Thromb. Res. 58 (1990) 331-341
15. Hosomi N., Lucero J., Heo J.H., Koziol J.A., Copeland B.R., and del Zoppo G.J. Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion. Stroke 32 (2001) 1341-1348
16. Johansson L., Jansson J.H., Boman K., Nilsson T.K., Stegmayr B., and Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 31 (2000) 26-32
17. Karges H.E., Funk K.A., and Ronneberger H. Activity of coagulation and fibrinolysis parameters in animals. Arzneimittelforschung 44 (1994) 793-797
18. Kosir M.A., Schmittinger L., Barno-Winarski L., Duddella P., Pone M., Perales A., Lange P., Brish L.K., McGee K., Beleski K., Pawlak J., Mammen E., Sajahan N.P., and Kozol R.A. Prospective double-arm study of fibrinolysis in surgical patients. J. Surg. Res. 74 (1998) 96-101
19. Lindgren A., Lindoff C., Norrving B., Astedt B., and Johansson B.B. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke 27 (1996) 1066-1071
20. Munkvad S. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways. Dan. Med. Bull. 40 (1993) 383-408
21. Ngo T.H., Verheyen S., Knockaert I., and Declerck P.J. Monoclonal antibody-based immunoassays for the specific quantitation of rat PAI-1 antigen and activity in biological samples. Thromb. Haemost. 79 (1998) 808-812
22. Ninomia T., Wang L., Kumar S.R., Kim A., and Zlokovic B.V. Brain injury and cerebrovascular fibrin deposition correlate with reduced antithrombotic brain capillary functions in a hypertensive stroke model. J. Cereb. Blood Flow Metab. 20 (2000) 998-1009
23. Nordenhem A., and Wiman B. Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes. Scand. J. Clin. Lab. Invest. 58 (1998) 475-483
24. Pfefferkorn T., and Rosenberg G.A. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 34 (2003) 2025-2030 Epub 2003 Jul 10
25. Ravanat C., Freund M., Schuhler S., Grunert P., Meyer L., and Cazenave J.P. Species specific immunoassays to measure blood platelet and coagulation activation in the rat. Thromb. Haemost. 76 (1996) 1090-1095
26. Ribo M., Montaner J., Molina C.A., Arenillas J.F., Santamarina E., Quintana M., and Alvarez-Sabin J. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 35 (2004) 2123-2127 Epub 2004 Jul 8
27. Schietroma M., Carlei F., Mownah A., Franchi L., Mazzotta C., Sozio A., and Amicucci G. Changes in the blood coagulation, fibrinolysis, and cytokine profile during laparoscopic and open cholecystectomy. Surg. Endosc. 18 (2004) 1090-1096 Epub 2004 May 12
28. Schneider D.J., Absher P.M., Neimane D., Russell J.C., and Sobel B.E. Fibrinolysis and atherogenesis in the JCR:LA-cp rat in relation to insulin and triglyceride concentrations in blood. Diabetologia 41 (1998) 141-147
29. Schreiber S.S., Tan Z., Sun N., Wang L., and Zlokovic B.V. Immunohistochemical localization of tissue plasminogen activator in vascular endothelium of stroke-prone regions of the rat brain. Neurosurgery 43 (1998) 909-913
30. Strbian D., Karjalainen-Lindsberg M.L., Kovanen P.T., Tatlisumak T., and Lindsberg P.J. Mast cell stabilization reduces hemorrhage formation and mortality after administration of thrombolytics in experimental ischemic stroke. Circulation 116 (2007) 411-418
31. Thiagarajan P., Rippon A.J., and Farrell D.H. Alternative adhesion sites in human fibrinogen for vascular endothelial cells. Biochemistry 35 (1996) 4169-4175
32. Thomalla G., Schwark C., Sobesky J., Bluhmki E., Fiebach J.B., Fiehler J., Zaro Weber O., Kucinski T., Juettler E., Ringleb P.A., Zeumer H., Weiller C., Hacke W., Schellinger P.D., and Rother J. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke 37 (2006) 852-858 Epub 2006 Jan 26
33. Tohgi H., Kawashima M., Tamura K., and Suzuki H. Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism. Stroke 21 (1990) 1663-1667
34. Ueda T., Hatakeyama T., Sakaki S., Ohta S., Kumon Y., and Uraoka T. Changes in coagulation and fibrinolytic system after local intra-arterial thrombolysis for acute ischemic stroke. Neurol. Med. Chir (Tokyo) 35 (1995) 136-143